Education 【 display / non-display 】

Education 【 display / non-display 】

• 　

  -

  1988

  Sapporo Medical University   School of Medicine   医学科  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 札幌医科大学   Ph.D.(Medical Science)

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2018.01

  -

  Now

  Sapporo Medical University   Center for Medical Education   教授

• 2018.01

  -

  Now

  Sapporo Medical University   Graduate School of Medicine   教授

• 2008.06

  -

  2017.12

  Sapporo Medical University   School of Medicine   准教授

• 2004.04

  -

  2008.05

  Sapporo Medical University   School of Medicine   講師

• 1999.10

  -

  2004.03

  Sapporo Medical University   School of Medicine   助手

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 2021.04

  -

  Now

  Japan Association for Medical Informatics

• 2018.04

  -

  Now

  日本医学教育学会

• 2010.01

  -

  Now

  International Society of Oncology & BioMarkers (ISOBM)

• 2009.01

  -

  Now

  THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

• 2005.01

  -

  Now

  Japanese Society of Molecular Medicine

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Genomics  

• Life sciences   Tumor biology  

• Life sciences   Gastroenterology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• 札幌医科大学   医療人育成センター 教養教育研究部門・生物学   教授  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• 癌抑制遺伝子

• 次世代シーケンサー

• p53関連遺伝子

• 消化器癌

• p53

display all >>

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Association of serum superoxide dismutase activity and the incidence of colorectal cancer in a nested case-control study.

  Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Hiro-O Yamano, Yasushi Sasaki, Hiroshi Nakase, Yingsong Lin, Kenji Wakai, Akiko Tamakoshi

  Cancer epidemiology   87   102455 - 102455  2023.09  [Refereed]  [International journal]

  　View Summary

  BACKGROUND: Superoxide dismutase (SOD) is an antioxidant enzyme that degrades superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and incidence of colorectal carcinoma (CRC) in a case-control study nested in the Japan Collaborative Cohort (JACC) study. METHODS: At baseline, 39,242 subjects donated serum samples. Participants diagnosed with CRC during follow-up were regarded as cases. Odds ratios (ORs) for CRC incidence associated with SOD were evaluated with conditional logistic regression models. In the current study, 176 cases and 524 controls were analyzed. RESULTS: For the overall cohort, a decreasing trend in risk of CRC with increasing SOD was observed (P for trend=0.054) and the fourth quartile of SOD level showed the lowest risk compared to the first (OR=0.52, 95% confidence interval [CI]=0.29-0.93). This was significant in men (P for trend=0.001), with the fourth quartile of SOD level showing the lowest risk compared to the first (OR, 0.23; 95%CI, 0.09-0.60). It was also exclusively observed for rectal cancer and left-sided CRC (P for trend, 0.037 and 0.020, respectively), with the fourth quartile again showing the lowest risk compared to the first (OR, 0.28 and 0.38; 95%CI, 0.09-0.84 and 0.16-0.91, respectively). Limiting subjects to those followed-up over 2 years, all trends remained unchanged. CONCLUSIONS: Our findings suggest that serum SOD activity correlates inversely with risk of CRC, particularly in men and individuals with rectal cancer/left-sided CRC.

  DOI PubMed J-GLOBAL

• Esophageal intraepithelial squamous cell neoplasia with epidermalization-A case with molecular analysis.

  Takao Endo, Toshiyuki Kubo, Yasushi Sasaki, Hiroaki Takahoshi, Yoshifumi Ishii, Yasushi Adachi

  Pathology international    2023.06  [Refereed]  [International journal]

  DOI PubMed

• Serum soluble Fas levels and incidence of liver cancer in nested case-control study.

  Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Toshiyuki Kubo, Noriyuki Akutsu, Yasushi Sasaki, Hiroshi Nakase, Yingsong Lin, Youichi Kurozawa, Kenji Wakai, Akiko Tamakoshi

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology   82nd  2022.12  [Refereed]  [International journal]

  　View Summary

  BACKGROUND: Soluble Fas (sFas) plays various roles in carcinogenesis and tumor dissemination by preventing apoptosis via binding to Fas ligand. We analyzed associations of serum sFas levels with the incidence of liver cancer in a prospective case-control study nested in the JACC Study. METHODS: A baseline survey was conducted from 1988, with blood samples obtained from 39,242 subjects. Patients diagnosed with liver cancer were regarded as cases. Two or three controls were selected and matched for sex, age, and geographical area. Conditional logistic regression was used to estimate odds ratios (ORs) for cancer incidence associated with sFas. RESULTS: This study contained 86 cases and 249 controls. After controlling for alcohol intake, body mass index, smoking, and hepatitis viral infection, participants with high sFas showed elevated risk of cancer (P-trend = 0.003) and the third tertile of sFas showed a higher risk compared to the first tertile (OR = 3.53, 95% confidence interval (CI) = 1.28-9.69). In hepatocellular carcinoma, high sFas was associated with elevated risk (P-trend < 0.001). In men and the elderly, subjects in the highest tertiles showed higher cancer risk. Limiting subjects to those followed for 3 years, high sFas was related to liver cancer risk (P-trend = 0.033) and the third tertile showed a higher risk compared to the first (OR = 2.94, 95%CI = 0.94-9.14). CONCLUSIONS: High serum sFas may be related to future risk of liver cancer. IMPACT: Our findings highlight this biomarker for further analysis in pooled investigations with different/larger prospective cohorts.

  DOI PubMed J-GLOBAL

• Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma.

  Yoshiharu Masaki, Noriyuki Akutsu, Yasushi Adachi, Keisuike Ishigami, Norikazu Iwata, Takao Endo, Yoshifumi Ishii, Yasushi Sasaki, Minoru Nagayama, Yasutoshi Kimura, Hiroshi Nakase

  Clinical journal of gastroenterology   15 ( 4 ) 809 - 817  2022.08  [Refereed]  [Domestic journal]

  　View Summary

  Intrahepatic mucinous cholangiocarcinoma (IHMC) is rare and behaves notoriously; however, the details of the clinicopathological characteristics of IHMC remain unknown. A 70-year-old man was admitted for examination of the hepatic mass in the S1 segment. He underwent extended left hepatic lobectomy. Histopathological evaluation demonstrated mixed papillary carcinoma that comprised well to moderately differentiated tubular adenocarcinoma and signet-ring cell carcinoma with large amounts of mucus lakes. Tumor was relapsed 9 months after surgery. Although he received chemotherapy with the combination of gemcitabine and cisplatin, he had renal failure and discontinued the chemotherapy. He received palliative radiotherapy for metastasis in the cervical spine. Then, the patient treated with S-1, however, he died 16 months after the initial diagnosis. The autopsy findings showed multiple nodules in the lungs, pleura, kidneys, adrenal glands, stomach, pancreas, and lymph nodes. Histological examination revealed that all nodules were IHMC. Next-generation sequencing revealed that somatic mutations in ADGRB3, TAF1L and EPHA3 may affect carcinogenesis, and those in TAF1, EPHA3, PIK3C2B, FN1, ERBB3, BRIP1, SYNE1 and TGFBR2 may affect metastasis. Molecular carcinogenesis of IHMC may be distinct from that of ordinary cholangiocarcinoma. Further studies are needed to elucidate the genetic mutations and their functions in IHMC.

  DOI PubMed

• Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.

  Ryunosuke Kogo, Tomomi Manako, Takeshi Iwaya, Satoshi Nishizuka, Hayato Hiraki, Yasushi Sasaki, Masashi Idogawa, Takashi Tokino, Ayaka Koide, Noritaka Komune, Ryuji Yasumatsu, Takashi Nakagawa

  Cancer medicine    2022.03  [Refereed]  [International journal]

  　View Summary

  There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment effect. We investigated whether individualized ctDNA analysis could help monitor treatment response and relapse in HNSCC. Mutation analysis of tumor and peripheral blood mononuclear cell (PBMC) DNAs of 26 patients with HNSCC was performed using a custom squamous cell carcinoma (SCC) panel. The identified individualized mutated genes were defined as ctDNA candidates. We investigated whether frequent ctDNA monitoring via digital PCR (dPCR) is clinically valid for HNSCC patients. TP53 was the most frequently mutated gene and was detected in 14 of 24 cases (58.2%), wherein two cases were excluded owing to the absence of tumor-specific mutations in the SCC panel. Six cases were excluded because of undesignable and unusable primer-probes for dPCR. Longitudinal ctDNA was monitored in a total of 18 cases. In seven cases, ctDNA tested positive again or did not test negative, and all seven cases relapsed after initial curative treatment. In 11 cases, after initial curative treatment, ctDNA remained negative and patients were alive without recurrence. Patients who remained negative for ctDNA during follow-up after initial curative treatment (n = 11) had a significantly better prognosis than those who reverted to ctDNA positivity (n = 7; p < 0.0001; log-rank test). Individualized ctDNA monitoring using SCC panel and dPCR might be a novel and promising biomarker for HNSCC.

  DOI PubMed

display all >>

Books and Other Publications 【 display / non-display 】

Books and Other Publications 【 display / non-display 】

• 分子標的療法の基礎と臨床

  佐々木 泰史, 時野 隆至( Part： Contributor, p53, p63, p73の機能とp53ファミリーを標的としたがん療法への応用)

  篠原出版新社  2005

• 内科疾患クリニカルガイド 消化器・免疫・血液・代謝疾患

  佐々木 泰史( Part： Contributor, 癌性疼痛治療の実際)

  中山書店  1999

• 日本臨床別冊巻 肝・胆道系症候群 肝臓編（上巻）

  佐々木泰史, 坂本裕史, 日野田裕治, 矢花剛( Part： Joint author, 肝粘表皮癌、肝内胆管粘表皮癌)

  日本臨床社  1995.04

• 血液学

  今井浩三, 佐々木泰史, 辻崎正幸( Part： Contributor, 原発性マクログロブリン血症)

  中外医学社  1991

• Therapeutic plasmapheresis VIII

  Suga M, Tsuchida M, Arimura Y, Matsuno K, Sasaki Y, Miyachi T, Ishida S, Yachi A( Part： Contributor, Basic and clinical evaluation of anion exchange resin column for treatment of jaundice)

  ISAO Press  1989

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 内視鏡的切除により診断できた皮膚様食道扁平上皮癌

  足立 靖, 菊地 剛史, 後藤 啓, 吉田 幸成, 石井 良文, 高橋 宏明, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫

  日本消化管学会雑誌 ( (一社)日本消化管学会 )  8 ( Suppl. ) 360 - 360  2024.01

• Association of serum superoxide dismutase activity and the incidence of colorectal cancer in a nested case-control study.

  Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Hiro-O Yamano, Yasushi Sasaki, Hiroshi Nakase, Yingsong Lin, Kenji Wakai, Akiko Tamakoshi

  Cancer epidemiology ( (一社)日本癌学会 )  87   102455 - 102455  2023.09  [International journal]

  　View Summary

  BACKGROUND: Superoxide dismutase (SOD) is an antioxidant enzyme that degrades superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and incidence of colorectal carcinoma (CRC) in a case-control study nested in the Japan Collaborative Cohort (JACC) study. METHODS: At baseline, 39,242 subjects donated serum samples. Participants diagnosed with CRC during follow-up were regarded as cases. Odds ratios (ORs) for CRC incidence associated with SOD were evaluated with conditional logistic regression models. In the current study, 176 cases and 524 controls were analyzed. RESULTS: For the overall cohort, a decreasing trend in risk of CRC with increasing SOD was observed (P for trend=0.054) and the fourth quartile of SOD level showed the lowest risk compared to the first (OR=0.52, 95% confidence interval [CI]=0.29-0.93). This was significant in men (P for trend=0.001), with the fourth quartile of SOD level showing the lowest risk compared to the first (OR, 0.23; 95%CI, 0.09-0.60). It was also exclusively observed for rectal cancer and left-sided CRC (P for trend, 0.037 and 0.020, respectively), with the fourth quartile again showing the lowest risk compared to the first (OR, 0.28 and 0.38; 95%CI, 0.09-0.84 and 0.16-0.91, respectively). Limiting subjects to those followed-up over 2 years, all trends remained unchanged. CONCLUSIONS: Our findings suggest that serum SOD activity correlates inversely with risk of CRC, particularly in men and individuals with rectal cancer/left-sided CRC.

  DOI PubMed

• 血清可溶性Fas値と肝臓癌罹患リスク(Serum soluble Fas levels and incidence of liver cancer)

  足立 靖, 野島 正寛, 森 満, 久保 俊之, 阿久津 典之, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫, 林 櫻松, 若井 建志, 玉腰 暁子

  日本癌学会総会記事 ( (一社)日本癌学会 )  82回   125 - 125  2023.09

• 非乳頭部十二指腸腫瘍におけるERBB受容体ファミリーの解析と治療標的の探索

  佐々木泰史, 澤田武, 中村慶史

  金沢大学がん進展制御研究所がんの転移・薬剤耐性に関わる先導的共同研究拠点   2022  2023

  J-GLOBAL

• Simultaneous cancers of the stomach and esophagus in autoimmune gastritis with pernicious anemia

  足立靖, 足立靖, 久保俊之, 久保俊之, 佐々木泰史, 安達靖代, 吉田幸成, 遠藤高夫, 石井良文, 高橋宏明, 後藤啓

  日本癌治療学会学術集会(Web) ( (一社)日本癌治療学会 )  61st   ICCJ1 - 3  2023

  J-GLOBAL

display all >>

Industrial Property Rights 【 display / non-display 】

Industrial Property Rights 【 display / non-display 】

• がんを処置するための医薬

  井戸川 雅史, 大箸 智子, 佐々木 泰史, 時野 隆至

  Patent

  J-GLOBAL

• p53ファミリーキメラ分子およびその使用

  時野 隆至, 井戸川 雅史, 佐々木 泰史

  Patent

  J-GLOBAL

• アポトーシス誘導剤

  特許第5630769号

  井戸川雅史, 佐々木泰史, 時野隆至

  Patent

  J-GLOBAL

• アポトーシス誘導剤

  井戸川雅史, 佐々木泰史, 時野隆至

  Patent

  J-GLOBAL

Other 【 display / non-display 】

Other 【 display / non-display 】

• 日本がん治療認定医機構 がん治療認定医（第09100061号）

  2010.04

  -

  Now

• 日本癌治療学会臨床試験登録医 （0985号）

  2004.08

  -

  Now

• 日本肝臓学会肝臓専門医（3150号）

  1999.04

  -

  Now

• 日本消化器内視鏡学会 専門医（0094005号）

  1994.12

  -

  Now

• 日本消化器病学会 消化器病専門医（21569号）

  1994.12

  -

  Now

display all >>

Awards 【 display / non-display 】

Awards 【 display / non-display 】

• 北海道医師会賞

  2021.10  

  Winner： Yasushi Sasaki

• 北海道知事賞

  2021.10   がん抑制遺伝子p53とそのファミリー (p73、p63)の機能解明

  Winner： Yasushi Sasaki

• 第14回日本消化器関連学会週間優秀演題賞

  2006.12   日本消化器関連学会週間  

  Winner： Yasushi Sasaki

• 第44回日本癌治療学会総会優秀演題賞

  2006.10   日本癌治療学会総会  

  Winner： Yasushi Sasaki

• 札幌医科大学医師会学術賞

  2003.03   札幌医科大学医師会  

  Winner： Yasushi Sasaki

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• p53の機能獲得変異に関わる小型タンパク質の探索と機能解明

  日本イーライリリー イノベーション研究助成

  Project Year :

  2023.12

  -

  2025.03

   

  佐々木泰史

  Authorship： Principal investigator

• p53ネットワークに関わるマイクロプロテインの探索と食道扁平上皮癌新規治療戦略

  科学研究費助成事業 基盤研究(C)

  Project Year :

  2023.04

  -

  2026.03

   

  佐々木 泰史

  Authorship： Principal investigator

• 非乳頭部十二指腸腺癌の2つの独立した発癌経路の検証とその分子機構の解明

  金沢大学がん進展制御研究所共同研究（一般研究、新規）

  Project Year :

  2023.04

  -

  2024.03

   

  佐々木泰史, 澤田 武, 中村 慶史, 源 利成

  Authorship： Principal investigator

• p53標的小型タンパク質の探索と機能解明

  2023年度 秋山記念生命科学振興財団 研究助成（一般）

  Project Year :

  2023.04

  -

  2024.03

   

  Yasushi Sasaki

  Authorship： Principal investigator

• p53の機能獲得変異は口腔扁平上皮癌の治療標的となり得るか

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2022.04

  -

  2025.03

   

  松田 亜沙実, 佐々木 泰史, 荻 和弘

  Authorship： Coinvestigator(s)

  　View Summary

  本研究では，癌抑制遺伝子TP53の変異を高頻度に認める口腔扁平上皮癌に着目し，TP53機能獲得変異によって起こるトランスクリプトームの変動を分析し，機能解析へと展開する．さらに発現異常，遺伝子変異の有無，悪性度および治療効果との関連性を解析することで，p53ネットワーク破綻のメカニズムを標的とした口腔扁平上皮癌の治療法開発の基盤形成を目指す．本研究の目的は，口腔扁平上皮癌をモデルとして，変異型p53のGOF（gain-of-function）によって変化するトランスクリプトームの全貌を解明し，p53ネットワークのさらなる理解につなげることである．変異型p53を標的とした治療法の開発につながる基礎研究を目指している．TP53のGOF変異は，がん遺伝子の活性化変異と類似の作用を示すことが予想され，新しい分子標的の同定に進展する可能性がある．
  本年度は以下の研究成果をあげた。 １）種々の細胞株に野生型，および3種の変異型p53（R175H, R249S, R273C）をアデノウイルスベクターを用いて導入し，非コードRNAに重点をおいたトランスクリプトーム解析を試みた．同定したトランスクリプトについては，qRT-PCRにより発現変化の再現性を順次確認し，変異型p53に発現変化する12の非コードRNAを同定した． ２）食道扁平上皮癌関連疾患である頭頚部扁平上皮癌26症例を対象に治療前後のctDNAの分析が治療効果と再発モニタリングに有用かを評価した。根治的治療後にctDNAが陰性化しない、または陰性化後早期に陽転化した症例全例で再発を認め、ctDNAが頭頚部扁平上皮癌の有望なバイオマーカーであることが示唆された。

display all >>

Committee Memberships 【 display / non-display 】

Committee Memberships 【 display / non-display 】

• 2022.04

  -

  Now

    日本電気泳動学会 評議員

• 2012.01

  -

  Now

    日本DDS学会 評議員

• 2011.01

  -

  Now

    日本臨床分子医学会 評議員

• 2010.01

  -

  Now

    日本癌学会 評議員

• 2005.01

  -

  Now

    日本消化器病学会 北海道支部評議員

display all >>

Social Activities 【 display / non-display 】

Social Activities 【 display / non-display 】

• 札幌医科大学ゴルフ部 顧問

  2014.04

  -

  Now

Academic Activities 【 display / non-display 】

Academic Activities 【 display / non-display 】

• Translational Oncology: International Advisory Review Board

• Gastroenterology Insights: Editorial Board

• Molecular Medicine Reports: Editorial Board